Protara Therapeutics, Inc. (TARA) - Dilution Analysis

10-Q filing | 57.5M shares outstanding

10-K filing | 54.1M shares outstanding

10-Q filing | 42.3M shares outstanding

10-Q filing | 42.3M shares outstanding

10-Q filing | 40.7M shares outstanding

10-K filing | 36.8M shares outstanding

8-K filing: The company completed a public offering of 13,690,000 shares of common stock and pre-funded warrants to purchase 2,325,372 shares at $6.25 and $6.249 respectively, and the underwriters partially exercised their option to purchase an additional 438,738 shares at the public offering price less discounts.

8-K filing: Protara Therapeutics, Inc. completed an offering of 13,690,000 shares of common stock and 2,325,372 pre-funded warrants at a price of $6.25 per share and $6.249 per pre-funded warrant, respectively, for gross proceeds of approximately $100 million. ($100.06M proceeds)

10-Q filing | 22.3M shares outstanding

10-Q filing | 21.2M shares outstanding

S-3 filing: S-3 filing indicates selling stockholders may sell shares of common stock from time to time.

10-Q filing | 20.6M shares outstanding

8-K filing: Protara Therapeutics, Inc. entered into a Subscription Agreement with certain purchasers to sell and issue 9,143,380 shares of common stock and pre-funded warrants to purchase 1,700,000 shares of common stock, accompanied by warrants to purchase up to 10,843,380 shares of common stock, with an expected closing on April 10, 2024, and aggregate gross proceeds of approximately $45 million. ($45.0M proceeds)

10-K filing | 11.3M shares outstanding

10-Q filing | 11.3M shares outstanding

S-3 filing: The company is filing an S-3 to offer up to $300,000,000 of common stock, preferred stock, debt securities, and warrants from time to time.

10-Q filing | 11.3M shares outstanding

10-Q filing | 11.3M shares outstanding

10-K filing | 11.3M shares outstanding

10-Q filing | 11.3M shares outstanding

10-Q filing | 11.3M shares outstanding

10-Q filing | 11.3M shares outstanding

10-K filing | 11.3M shares outstanding

10-Q filing | 11.2M shares outstanding

10-Q filing | 11.2M shares outstanding

10-Q filing | 11.2M shares outstanding

10-K filing | 11.2M shares outstanding

S-3 filing: The filing is an S-3 registration statement for a shelf offering of common stock, preferred stock, and debt securities, allowing the company to offer up to $300,000,000 in one or more offerings from time to time.

10-Q filing | 10.5M shares outstanding

8-K filing: Protara Therapeutics, Inc. entered into underwriting agreements for concurrent public offerings expected to result in gross proceeds of approximately $147.6 million, including the offering of 4,600,000 shares of common stock at $16.87 per share and 4,148 shares of Series 1 Preferred Stock at $16,873.54 per share.

10-Q filing | 5.8M shares outstanding

S-3 filing: Protara Therapeutics files an S-3 form to register a shelf offering of common stock, preferred stock, and debt securities, with a total aggregate offering price of $150,000,000.

10-Q filing | 5.8M shares outstanding

8-K filing: ArTara Therapeutics, Inc. adopted the ArTara Therapeutics, Inc. Inducement Plan, reserving 600,000 shares of the Company's common stock for issuance under the plan.

10-K filing | 5.8M shares outstanding

S-3 filing: This S-3 filing covers the offer and resale by selling stockholders of up to 5,776,244 shares of common stock.

8-K filing: The company completed a private placement on January 9, 2020, selling 1,896,888 shares of common stock at $7.01 per share and 3,879.356 shares of Series 1 Preferred Stock at $7,011.47 per share, for an aggregate purchase price of approximately $40.5 million. ($40.5M proceeds)